Brief: DBP: no serious adverse effects in GLP-tox preliminary study for Temodex
16/10/2017 07:16
Oct 16 (Reuters) - DOUBLE BOND PHARMACEUTICAL INTERNATIONAL
AB (PUBL) DBPHAb.ST :
* NO SERIOUS ADVERSE EFFECTS IN GLP-TOX PRELIMINARY STUDY
FOR TEMODEX
Source text for Eikon: ID:nWkrgH7w9
Further company coverage: DBPHAb.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Double Bond Pharmaceutical International AB (publ)
See all newsBrief: DBP International AB And Vivo Biopharma LLC Revised Asset Purchase And Collaboration Agreements
Brief: DBP International AB And Vivo Biopharma LLC Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
Brief: DBP And Vivo Enter Into Asset Purchase And Collaboration Agreements To Develop And Commercialize A Novel Glioblastoma Treatment
Brief: Double Bond Pharmaceutical Says Positive Response For SI-053 From Ethical Committee In Netherlands Has Been Received
Brief: Double Bond To Cooperate With Belarus State Medical University